Resveratrol is a polyphenol found in red wine that possesses a wide range of biological effects and has anti-oxidant properties. All these biological effects are related to NF-úB pathway which it is thought to be dysregulated in CF patients secondary to CFTR dysfunction. Aim: To investigate the potential impact of resveratrol on CFTR function in CF mice. Methods: Three weeks apart, nasal potential difference measurements (NPD) were performed in 5 CF mice homozygous for the F508del-CFTR mutation in the 129/FVB outbred background (a) without treatment (baseline) and (b) after intraperitoneal injection of resveratrol (20 mg/kg) diluted in physiological serum. Normal distribution of NPD measurements was confirmed by Shapiro test. Between-groups comparisons were evaluated using paired ANOVA coupled to t Test. Results: Total chloride secretion improved from 4.8±3.5 mV (baseline) to 11.7±3.4 mV (Resveratrol) (P = 0.015). Baseline PD and response to amiloride were not modified. Conclusion: Total chloride secretion improved with resveratrol. These preliminary data prompt us to further study the potential effect of resveratrol in cystic fibrosis.
Defective CFTR chloride transport is a prominent feature in cystic fibrosis (CF). The s-cis-locked cycloheptathiazolothiazole 29 (corrector-29) was previously designed and identified as the most potent bithiazole corrector of defective DF508-CFTR with EC 50 in vitro~450 nM (Yu et al., J. Med. Chem. 51: 6044-6054, 2008) . However, its efficacy in human tissues has not been reported. The purpose of this translational study was to evaluate the efficacy of corrector-29 on DF508-CFTR in human CF epithelia. We performed transepithelial short-circuit current (I sc ) measurements in primary cultures of human bronchial epithelial (HBE) cells and ex vivo native rectal biopsies from DF508-CF and non-CF subjects. CFTR immunoblot analysis was done on the same rectal biopsies. After 24 h incubation at 37ºC with 10 mM corrector-29, there was a vehicleindependent, forskolin-stimulated increase in DF508-CFTR-mediated chloride secretion of 5.4±0.3 mA/cm 2 (S.E.) in HBE cells (n = 8) and of 4.5±0.5 mA/cm 2 in rectal biopsies (n = 16), indicating~25% of normal CFTR function in non-CF controls. CFTR immunoblot analysis showed an increase in mature CFTR protein (band C) in DF508-CF rectal biopsies incubated with corrector-29 but not in untreated biopsies. These data provide evidence for substantial DF508-CFTR correction by corrector-29 in disease-relevant human CF epithelia and support the utility of ex vivo assays in native rectal tissue for CF drug development. Preclinical testing of candidate CF drugs can help to prioritize and optimize compounds for translation into clinical trials. This work was supported by CFF, CFRI and the Christiane Herzog Foundation. 
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